The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in nonobese japanese patients with non-insulin-dependent diabetes mellitus: A pilot study

Abstract

This study examined the effects of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in 10 nonobese patients with non-insulin-dependent diabetes mellitus (NIDDM). Plasma glucose levels before and at 2, 3, 4, 6, 8, 10, 15, 20, and 30 minutes after administration of the intravenous glucose tolerance test (IVGTT) were significantly ( P < 0.05) decreased after administration of CS-045 (400 mg/d) for 8 weeks. However, no significant changes in plasma glucose levels were noted at points measured from 45 to 180 minutes after administration of the drug. Plasma immunoreactive insulin (IRI) levels at the 15 minute-point during the IVGTT were significantly ( P < 0.05) decreased after administration of CS-045, but there were no significant changes at any other point before or during the test after administration of the drug. Area under the curve of plasma glucose and IRI at each point in time of the IVGTT was significantly ( P < 0.05) decreased after administration of CS-045. Levels of serum total cholesterol, low-density lipoprotein cholesterol, triglyceride, and free fatty acid levels were significantly ( P < 0.05) decreased and high-density lipoprotein cholesterol was significantly ( P < 0.05) increased after administration of drug. These results indicate that CS-045 is an effective oral hypoglycemic agent that improves glucose tolerance and abnormal serum lipids levels in nonobese NIDDM patients.